Calendar Opportunities Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2025 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Solriamfetol 300 mg - Phase 3 | AXSM Pipeline | CatalystAlert

Solriamfetol 300 mg

Phase 3

Axsome Therapeutics, Inc. (AXSM)

Phase 3

Development Phase

0

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Development History

Dec 2025~

AXSM⭐Phase 3

Solriamfetol 300 mg Phase 3 Results Expected

Solriamfetol 300 mg • Binge-Eating Disorder

Drug Information

Target Indication

Binge-Eating Disorder

Clinical Trial

Last updated: 12/4/2025

Developer

AXSM

Axsome Therapeutics, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

AXS-07 (meloxicam-rizatriptan)Phase 3

Migraine

AXS-12 (reboxetine)Phase 3

Narcolepsy

Solriamfetol 150 mgPhase 3

Excessive Sleepiness

Narcolepsy

AXS-07 (MoSEIC meloxicam and rizatriptan)Phase 3

Migraine

View full pipeline